IDEXX LABORATORIES INC /DE (IDXX): Results of Operations and Financial Condition
IDEXX LABORATORIES INC /DE (IDXX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 IDEXX Laboratories Announces Second Quarter Results ▪ Achieves second quarter revenue growth of 10% as reported and 9% organic, and CAG Diagnostics recurring revenue growth of 11% as reported and 10% organic. ▪ Strong volume-driven CAG Diagnostics recurring revenue g
How this was made
The 30-second read
Why it matters
Traders can update models using the narrowed revenue range, raised EPS range, and the stated drivers: CAG Diagnostics recurring revenue performance, operating margin expansion, and FX headwinds.
Market read
The filing provides fresh, quantified guidance changes for 2026 (revenue, organic growth, operating margin, EPS) tied to recurring diagnostics momentum.
What to watch
CAG Diagnostics capital instrument revenues declined 19% reported and 20% organic, which could cap near-term instrument-related growth even as recurring revenue accelerates.
IDEXX reported $1,217 million of second-quarter revenue, up 10% as reported and 9% organic, while EPS increased 18% as reported to $4.27 and the company raised the midpoint of its 2026 revenue and EPS outlooks.
Second-quarter revenue, CAG Diagnostics recurring revenue, gross margin, operating margin and EPS all increased, supported by volume-driven recurring diagnostics growth, utilization expansion and net price realization. Management also increased the midpoint of its full-year revenue and EPS outlooks while raising its operating-margin outlook.
Key metrics
as reported| Metric | Value | q/q | y/y |
|---|---|---|---|
| Revenueother | $1,217 million | – | 10% as reported and 9% organic |
| Earnings per diluted shareother | $4.27 | – | 18% as reported and 15% on a comparable basis |
| EPS tax benefits from share-based compensationother | $0.14 per share | – | – |
| EPS benefit from year-over-year currency changesother | $0.06 per share | – | – |
| Gross profit growthother | 12% as reported and 11% on a comparable basis | – | 12% as reported and 11% on a comparable basis |
| Gross marginother | 64.0% | – | increased 140 basis points as reported and 120 basis points on a comparable basis |
| Operating marginother | 35.0% | – | higher than the prior year period by 140 basis points as reported and by 110 basis points on a comparable basis |
| Operating expense growthother | 10% as reported and 9% growth on a comparable basis | – | 10% as reported and 9% growth on a comparable basis |
| CAG revenue growthother | 9% as reported and organic | – | 9% as reported and organic |
| CAG Diagnostics recurring revenue growthother | 11% as reported and 10% organic | – | 11% as reported and 10% organic |
| IDEXX VetLab consumables revenue growthother | 15% reported and 14% organic | – | 15% reported and 14% organic |
| Reference laboratory diagnostic and consulting services revenue growthother | 11% reported and 10% organic | – | 11% reported and 10% organic |
| Rapid assay products revenue growthother | 1% as reported and on an organic basis | – | 1% as reported and on an organic basis |
| CAG Diagnostics capital instrument revenue growthother | decreased 19% as reported and 20% on an organic basis | – | decreased 19% as reported and 20% on an organic basis |
| Veterinary software, services and diagnostic imaging systems revenue growthother | 12% on a reported and organic basis | – | 12% on a reported and organic basis |
| Water revenue growthother | 15% as reported and 13% organic | – | 15% as reported and 13% organic |
| LPD revenue growthother | 11% as reported and 9% organic | – | 11% as reported and 9% organic |
| IDEXX inVue Dx placementsother | over 1,600 | – | – |
| IDEXX inVue Dx installed baseother | surpasses 9,000 instruments | – | – |
| IDEXX global premium instrument installed base expansionother | 11% | – | 11% expansion |
2026 outlook
- Revenue$4,700 million - $4,745 million
- Tax rate~ 21.1%
- NoteReported revenue growth: 9.1% - 10.3%
- NoteOrganic revenue growth: 8.5% - 9.7%
- NoteCAG Diagnostics recurring revenue reported growth: 10.1% - 11.3%
- NoteCAG Diagnostics recurring revenue organic growth: 9.5% - 10.7%
- NoteOperating margin: 32.3% - 32.5%
- NoteOperating margin expansion: 70 bps - 90 bps
- NoteComparable margin expansion: 70 bps - 90 bps
- NoteEPS: $14.69 - $14.94
- NoteEPS reported growth: 12% - 14%
- NoteEPS comparable growth: 13% - 15%
- NoteNet interest expense: ~ $35
- NoteShare-based compensation tax benefit: ~ $19
- NoteShare-based compensation tax rate benefit: ~ 1.3%
- NoteShare-based compensation EPS impact: ~ $0.24
- NoteReduction in average shares outstanding: 1.5% - 2%
- NoteOperating Cash Flow (% of Net Income): 110% - 120%
- NoteFree Cash Flow (% of Net Income): 90% - 100%
- NoteCapital Expenditures: ~ $180
- NoteEstimated foreign currency revenue growth rate impact: ~0.6%
- NoteEstimated foreign currency CAG Diagnostics recurring revenue growth rate impact: ~0.6%
- NoteEstimated foreign currency operating margin growth impact: ~ 30 bps
- NoteEstimated foreign currency EPS impact: ~ $0.22
- NoteEstimated foreign currency EPS growth impact: ~ 2%
What drove it
- CAG Diagnostics recurring revenue growth was driven by strong volume gains, net customer expansion, IDEXX innovation and growth of the premium instrument installed base.
- IDEXX VetLab consumables growth reflected testing utilization gains, recent product launches, net new customer growth and net price gains.
- Reference laboratory diagnostic and consulting services growth was driven by higher testing volumes and net new customer gains.
- Gross-margin expansion was supported by recurring-revenue volume gains, operational productivity initiatives and net price realization.
- Operating-expense growth supported commercial-capability expansion, innovation and enabling information-technology investments.
- Water growth reflected organic growth in the U.S. and Europe, while LPD growth was led by the Americas.
Concerns
- CAG Diagnostics capital instrument revenues decreased 19% as reported and 20% on an organic basis, as the comparison lapped Q2 2025 broad availability of IDEXX inVue Dx.
- Rapid assay products revenues increased 1% as reported and on an organic basis, with volume impacts from adoption of the Catalyst Pancreatic Lipase Test shifting testing across modalities.
- Updated foreign exchange estimates reduced projected 2026 revenues by $15 million and represent an estimated ~ $0.22 EPS impact for 2026.
- Management plans incremental investments aligned with commercial and innovation priorities.
What to watch
- CAG Diagnostics recurring revenue performance against the 2026 reported growth outlook of 10.1% - 11.3% and organic growth outlook of 9.5% - 10.7%.
- The pace of IDEXX inVue Dx placements and expansion of the premium instrument installed base.
- Whether gross-margin performance supports the 2026 operating-margin outlook of 32.3% - 32.5%.
- The effect of updated foreign currency estimates on 2026 revenue growth, operating margin and EPS.
- Performance in CAG Diagnostics capital instruments following the Q2 2025 IDEXX inVue Dx availability comparison.
Balance sheet and cash flow
- 2026 Operating Cash Flow (% of Net Income) outlook: 110% - 120%.
- 2026 Free Cash Flow (% of Net Income) outlook: 90% - 100%.
- 2026 Capital Expenditures outlook: ~ $180.
Analysis
IDEXX reported $1,217 million of second-quarter revenue, with growth of 10% as reported and 9% organic. CAG grew 9% as reported and organic, while CAG Diagnostics recurring revenue grew 11% as reported and 10% organic. Water and LPD also contributed growth of 15% as reported and 13% organic, and 11% as reported and 9% organic, respectively. The release attributes the recurring diagnostics result to volume gains, customer expansion, innovation, premium-instrument installed-base growth and utilization.
The underlying product mix favored recurring revenue. IDEXX VetLab consumables grew 15% reported and 14% organic, and reference laboratory diagnostic and consulting services grew 11% reported and 10% organic. In contrast, CAG Diagnostics capital instrument revenue decreased 19% as reported and 20% organic while lapping Q2 2025 broad availability of IDEXX inVue Dx. Current-quarter instrument activity still included over 1,600 IDEXX inVue Dx placements, and the installed base surpassed 9,000 instruments.
Profitability expanded alongside revenue. Gross profit increased 12% as reported and 11% on a comparable basis, and gross margin reached 64.0%, up 140 basis points as reported. Operating margin was 35.0%, up 140 basis points as reported, despite a 10% increase in operating expenses as reported. Management identified recurring-revenue volume, productivity initiatives and net price realization as gross-margin supports, while operating spending funded commercial capabilities, innovation and information technology.
EPS was $4.27, increasing 18% as reported and 15% on a comparable basis. Second-quarter EPS included $0.14 per share in share-based-compensation tax benefits and a $0.06 per share benefit from year-over-year currency changes. The release did not provide second-quarter net income, operating income, cash flow, cash or debt figures in the supplied text.
For 2026, IDEXX narrowed revenue guidance to $4,700 million - $4,745 million, raising the midpoint by $5 million despite a $15 million reduction to projected revenue from a stronger U.S. dollar. The company raised its organic revenue growth outlook and its operating-margin outlook to 32.3% - 32.5%. EPS guidance increased to $14.69 - $14.94, with the midpoint reflecting $0.14 per share from operational performance, $0.05 from higher share-based-compensation benefits and a $0.05 foreign-exchange headwind.
Management, verbatim
Our second quarter results reflect the strength of our Technology for Life strategy, with continued innovation across our Catalyst, Fecal Dx, and IDEXX inVue Dx platforms supporting deeper customer adoption and higher diagnostic utilization.
Mike Erickson, President and Chief Executive Officer
This is the kind of durable, compounding growth we're building for the long term, helping veterinarians see more and do more for their patients while creating lasting value for our shareholders.
Mike Erickson, President and Chief Executive Officer
Not in the filing
stated, not guessed- Period-end date.
- Second-quarter GAAP net income.
- Second-quarter operating income.
- Second-quarter gross profit amount.
- Second-quarter operating expenses amount.
- Prior-year and prior-quarter absolute figures for revenue, EPS, gross profit, gross margin, operating margin and operating expenses.
- Dollar revenue for CAG, CAG Diagnostics recurring revenue, Water, LPD and the reported CAG subcategories.
- Second-quarter operating cash flow.
- Second-quarter free cash flow.
- Cash balance.
- Debt balance.
- Share repurchases, dividends and other reported capital returns.
- A separately supplied previous-release outlook section for actual-versus-prior-guidance comparison.
AlphaAI analysis generated from the company’s SEC earnings filing (Form 8-K Item 2.02, or Form 6-K for a foreign private issuer). Every figure was cross-checked against the filing text; consensus estimates, price targets and share-price reactions are not shown because they are not in the filing. AI-generated research, not investment advice.
Background
This is an SEC Form 8-K (Item 2.02) with Exhibit 99.1 covering IDEXX’s Q2 2026 results and updated full-year 2026 guidance.
Ticker impact
IDEXX reported Q2 2026 revenue growth of 10% and EPS of $4.27, and narrowed 2026 revenue guidance to $4,700-$4,745M.
Likely positive near-term bias as traders reprice 2026 growth and margin trajectory; watch for FX headwind sensitivity.
The filing provides specific, updated full-year ranges (revenue, organic growth, operating margin, EPS) and ties them to CAG Diagnostics recurring performance and operating margin expansion.
Market effects
Supports the view that veterinary diagnostics and recurring consumables/software are sustaining mid-to-high single digit organic growth with margin expansion.
International CAG Diagnostics recurring revenue growth is cited as 14% reported and 12% organic, implying strength beyond the U.S.
FX is explicitly called out as a $15M headwind to revenue, highlighting currency sensitivity for global investors.
Counterpoint
The guidance update is modest at the midpoint and includes a stated FX headwind, so upside may be partially accounting-driven rather than purely operational.
Key entities
- companyIDEXX Laboratories, Inc.
Pet healthcare and diagnostics company reporting Q2 2026 results and updating 2026 revenue and EPS guidance.
- business_segmentCAG Diagnostics
Companion Animal Group diagnostics recurring revenue stream cited as the main driver of growth and guidance changes.
- product_platformIDEXX inVue Dx
Installed base and placements are highlighted as supporting recurring diagnostics utilization.
